Skip to search formSkip to main content

Hypoxia-activated Prodrug TH-4000

Known as: TH-4000 
A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is… Expand
National Institutes of Health

Related topics

Related topics

2 relations
PR610Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC.
e13548 Background: TH-4000 is a clinical-stage hypoxia-activated prodrug that releases an irreversible tyrosine kinase inhibitor… Expand
Is this relevant?
Review
2015
Review
2015
Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial
Clinical data indicate that mutant EGFR NSCLC is often heterozygous (PLoS ONE 2013; 8: e54170; PLoS ONE 2009; 4: e7464) and the… Expand
Is this relevant?
2015
2015
The Hypoxia-Activated EGFR-TKI TH-4000: Preclinical Profile and Ongoing Clinical Studies in NSCLC, SCCHN, and SCCS
 
Is this relevant?